you, and good morning, Nasrat manufacturing, answer you R&D, questions Thank for an you Chairman our and joining am distribution, give and Diane. some summary is of submitted sale the will is and a I financials, ladies update name year-end of you on Matthew, I company's have that and gentlemen. to earnings CEO. This Elite's us Thank today. Hakim, call. Elite’s My the
let received wait CFO end. the start want to issue till I questions address and don't our subject few the a of me I Before Diane the Since vacancy. about
we we in it, a XX-years. family We over our whom not and a here. opportunity while a contact him good and got wished Ward he with today. person, was here to well stay encouraged than because as him stockholder, good is have CFO And Carter for and lot match, been we till take that have could elsewhere great I a he, Carter longer his good He CFO
you to got to you're and SEC Anytime his industry are and make he really was [Indiscernible] did to and in to But to would took with want Mark not promoted He have a decision used as He on the all resigned. and I that when actually a to time, and helped chance gentleman, times you old and like the good the was working to back he subject are a consult not. at him scanning regulated was nothing The you SEC We every pressure job. auditors got controller go you to work. job. he to choice a the where us The small you're his it he subject decent further who for we good. him successor. recruit made emphasize When it. for a leave. the two will CFOs you out a I of about everybody. to company, say next respect the did CFO,
right. All
XX-K Section sec.gov on a elitepharma.com. financials. As for pleasure have provide March filed we to at our is is the our available and It year ending the the at Investors on updating fiscal March XXXX. filings. XX, our Yesterday, least year, websites I today, for is the our on XX-K of copy CFO the wonderful acting you a link many of in also other of website that posted Elite
primarily I'll approximately Last financial start statement. the XXXX. million had ending We million $XX had this million, update year, $X year the last $XX with in we Loxapine is during million to compared our of tablets previous to cost Naltrexone the Adderall, capsules. the This generic this million. year. and compared $XX.X sales sold year goods it's to of sales up year fiscal with $XX million, $XX.X of about income the of was record The version
this goods spent Previous The an than posted million million spent million $X.X year. more year operating we about profit driven increases cost increase of revenues decrease in held Now We in $X as by previous constant. operating million, rule, million year spending R&D in an in million was over the profit primarily increase approximately of of million, revenues, $X.X $X previous compared have cost we the $X.X increase. a goods about as general million, year. XXXX. Despite usually to a of $X.X the $X $X
Our primarily interest previous was million increase the The to year operating million, outstanding loan. $XX in increase R&D of expenses on of $XX our million. over $X million increase related of and million an $X spending, approximately were that's $X
Let's our sheet. move balance to
is the previous during million, capital $XX.X to compared $XX.X working Our million year.
is cash Our year XXXX. compared million, $X.X down the et previous from we cetera from operating of for activities R&D expenses the to million, $X.X reasons spoke in
March East million Our total was is $X.X West loan to $XX Bank. cash after we That hand on million of as XX, a paid XXXX.
part a of the loan to loan money, use $XX that million working to the termination a Due a sales. covenants this agreement, increased Bank bank our allow longer for to would Elite's of direct Let capital intended words that purpose. West compared have full had us continue not majority longer direct the Elite loan. we me sales and we terms restrictive for repayment inventory recently the say require transition us and it time, time to access requirements on hold a from loan about charging of Lannett's East couple licensing product. but as Payment the we repaid. for to
right the to XX%. million the Bank without a West year year us outstanding on interest us. a decided having to restrictions in elsewhere. that Therefore, it under company to sales the $X two to loan to second by in decided the allow reduce raise Elite It capital The to put by Elite and new million This is one one a loan place short-term same support to with terms to without be $X to the off needed short-term put years. restrictions. Bank, on loan East the raise provides a East money West the as loan It's the pay also only paid but the loan proposal transition. will working extend for debt This
didn't it. on borrowed million, So conditions we with pay actual instead need using not we except paying money to Elite all kind $XX million, really exact it, paying so $XX million. had of, less interest million and Same interest of $X of interest the on we're, $X
$X may pause in how million may we see week I to raise the do far, that's we okay? We before contributed have here have do with willing two, but reduce million is potential of for see coming this, That so to capital of are the investors the working we pause and the borrowing how us this money. And that. and help now and cost other we queue to that is there interest $X in continue mainly working and
That have $X.X important in in $XX I is XXXX, $XX for us. past years. a Elite's by XXXX, was years, fact XXXX, in an XXXX; in excellent year In and fiscal now period Now $XX the year revenues to is of news sales our million short annual million five drastically fiscal increased highlight million trend XXX%. five on fiscal year. for million progressive this $XX million been have
The is shown the the news over undeniable, in price is that marketing, better months, where next inversely sales do, now and go that we is value we we few bad growth this be. own stock an proportional it our gets business to our we not adjustment started still continue. though want to is price period past will The achievements. it the in we the the disappointing through Once trend year-after-year, five have years, less our stock quarter-after-quarter, even and
development. mentioned months. annually target during date, and The in will substantially -- December, few number the when few resend product $XX to $XX and revenues From be we north they you let's say January the million give this months continues invest after of higher be it pipeline. January to last million. Elite I We today. need -- to in continue revenues like that need a in to To just invest I would say conference XXXX trend, will call. to the R&D. are of feed
to and agonist as and under These Our today. a filed generic generic dopamine a we ANDA. is two goal portfolio. competitive are ANDA new recently commercialize by products Elite diversify antimetabolite a ANDAs, review two FDA grow our
study. In intends filing. contains we're partial for by pain of FDA. addition, the conducted remaining this the while XXXX with in The FDA application disclosed a working to company a the back submitted complete recently continued insufflation on We management review the actually QX for provide ANDA to data Elite insufflation that the And about and it, we is this on $X the why was and million, time had put cost we everybody the deficiencies last is It prohibitive. an filed of $X.X study was conducted. deficiencies project generic of that we million, study That version that got alone is hold. Oxycodone. one partial not
turning opioid and Once the federal the world they are things everybody in they sue states and can the we government and settled can learn that the have sued everything settle.
years to five switching we next to is under going come managed are believe pendulum control. that three the Now opioids in really the and back
how sterilization to at each or the where release realization, and come bottle where pharmacy each before can have we up exactly Nowadays, okay? in we FDA house whose That's anything, what here bottle not lot, have know ended works. actually
demanded the have we prescriptions use. the that all per have to and about at patients or also you of have likely have prescription where educate days amount that cannot FDA It also automatic can we They the the you tablets doctors home reduce refill. the RIMs
doctor. to have to You go the
You amount. can specific get a
factors these And started is to in in back getting why on opioids are this all market of this opinion. working So the we my product.
just were that there make punch want to doing the we because we we the us going them same made the announcement wanted an study, we're are positive the learned to Once we companies did resourced and knowing are an thing other insufflation we to that But we to results and are announcement. did by then that three not that file. beat
about be to an a hopefully So usually tell now to application once you by going, should the they XX That partial and okay? it. to filed it. would do, takes I we August days we accept get file quiet, we'll XX till full Xst FDA The application And announcement. and had make date the be wait can PDUFA
has All BE now right. pilot formulation the the phase the are in phase. that They have are moved Elite from and three phase. in development clinical products
ongoing. pilot conducted have the BE study studies We BE or is the studies or
stage. has future that have development Elite For entered other products the formulation growth,
filing We you reach as other will approval. when or milestones update we certain such development on products
system did In second functional you have FDA recognize from full R&D have a and because that the approval, as take that. to system, R&D a with get formulations they're are and revenues me company summarize going order Let to you a have pending approved financials. I to R&D and
you've doing have these vetted for have can or process, you're or or capsule, that trials that they FDA. are just are to us to have which the with you yes, the the And for company, to good some an to our clinical release need on versus we extended filing have, injectable. some You tablet products fit close do
now, formulation What you stage. products have just are to right that we described in I the
two have clinical are that are with FDA. and the in We stage three
fully a functional R&D have We system.
If that, positive and we by got for and one The of the beyond is them. are material are mean a contribution hit the clinical all that I mentioned the the of of as they second products if we movers. good be Elite impact have very that any revenue thing the them trend will of is three continue I that from all emphasize company them, on three If the approved. want stage What a needle we'll that to them would in stockholders. approved, result day XXXX XXXX I
I We sales Elite's a year. ending strong licensees. year our and profits through growth today XXXX. The our are are on year mean fiscal and XXst, this sales -- of are that invested March pipeline and with creating invested finished Amphetamine, some the year before. of revenues ER. this year continued products saw our largest revenue in from the We IR the organization. our These and And We bringing products distribution development by
expect to continue to that be under We label. them Elite's
We place to and have shares we double-digit with marketing our in products. expect these maintain contracts
a always Management of is the challenger. quota DEA
manage the much of And been market. on April we I few month improve. April, Kirko were to were IMS Amphetamine or this to Lannett. have A the definitely minutes from IQVIA we came has X.XX% I and a to are the for of got for with number remains expect May, both shortage everything material demand. month launched through on FDA challenge out that for Elite the just However, products able data command IR in ago, call list the in launch, didn't making for and of IR, the we that to-date. because
increase under is and one the Elite's is important. of interesting sold an Isradipine although we Xst Trimipramine can that believe opportunity particular only in being are and direct volume. sales, Both have with this as April modest now really of Isradipine competitor products label in and value Elite product.
make Isradipine margins bottom a in contributing difference Elite. And so to line can the of
two competitors Pricing products that and and two the they of a margins, despite competitors. and contribution expect be shortage the will been has are to despite coming April are will company of off because the do Elite’s as in -- Loxapine be Dantrolene challenging though we also list. label FDA of few to Xst. recently be transitioned will they Loxapine making have profit. only a of margins a Both players we making But hopefully field healthy only
will as licensees we continue products, well. to License selected through sell products
For and introducing warehouse The been continue example, TAGI for equipment. for Naltrexone once that's more increase our in new products partner and to us sales sell decade employees, ANDAs approved, are with us. long-term we’ll more and half, are a a the more require storage space Phentermine
manufacturing. it the the for now. But will is upgrading in equipment several And to are another of We keep is our to point with process we have the sales to where demands. of plan in up time to pieces have support facility facility there a
of it's important projects the It's an project, my expensive most that's but on one mind.
affect have within we the us zone or to in a make impact only them the these need years the Decisions we continue future think three-years plus few need time them going Decisions executive, today to to to us three-year future. same. planning minus, As decisions, we always do better. an and ago refining not make you are today. and made to We adjusting in
For or to technology, [art] creating the our really approach okay? today, that and did when what three-pronged R&D, decision slowing profitable we three own is approach, (ph) partnerships basket led SunGen us combo that amphetamine made and developing example, the
as art dollars, the of On millions believe borrowing money. of study these kept asking part, dollars draining technology, was cost the millions down first don't and more slowing each for FDA it more and will the and in I
us ending we that So and in our address because point we Slowing our company we give second. an for and were as a selling it attention sight there have can't product is today. did focusing combo amphetamine own like And anymore, the where and shares look we and that. today we'll partnerships us that doesn't made products down give on we do us a and the viable that
is bankrupt today the If we like will in for Elite be we money survived, company. art though back support did corn though the even borrowed took hope technology, same It stockholders coming didn't. been the the zero our got they not over financials. be detectors low, money and even hope bankrupt. have to money, and private has The a we even actually then it but to in if like But will whole whom back great even zero because we and of the be the would make stockholders order zero opportunity position borrowed our it. us stock Lannett, if will there and
distribution Okay. Sales and these and is sales -- one marketing of instances.
sales of and another to one addition In of thinking plan, distribution another these is instances.
approval with you March licensing give SunGen growing for and for three-year XXXX, would the about remember ER, and partners Lannett for the in extended agreement got Lannett interesting Elite with Lannett understand same all did licensing decided November we to of and by the to when and background got to marketing, two we and their month and IR Just engaged IR so job XXXX, and that a March and know a years they how net extend Lannett ER. at good that end of in historic it then XXXX. here, a sales have that's amphetamine sales XXXX. we It us amphetamine you that the the was agreement ER.
wall. another we future, planning writing into happened, action Well, when distributor, the looking and sold start sales XXXX company's the we because marketing on start responding or immediately into that the for by and
in three XXXX outstanding. for We was was to a of still Now [Indiscernible] about and my candidates, selected course, and starting to started it four, me, month number of two VP sales. January of or Kirko candidates, who bother in met opinion solid interviewed I screened after search a of very we we several
have they risk In problems, it, don't head just to hey, the you're want list for and like, financial July making on to want placed then, the they they're on way them they and discontinued it. assure tried the taking selling Even issues, they up worry, approval the IR XXXX, they sell for received GMP and all their me don't this, discontinued it list. amphetamine. everybody There is with it making put no to Lannett
And I said, no.
exercised and We and continue all termination in six Lannett month marketing. shortly somebody after, trying to to licensed states, get own our enough XX sales agreement. hiring this for clause planning in the do Sure
and believe of somebody to notice month issued did, states to want September him of for from Within Dantrolene we of Trimipramine background notice want termination to with bring Kirko. I Isradipine We of month we notice brought Epic we and of who's that back, months going When hey, home also hired got we've got XX because all or immediately we home March September, products a our we six because everybody the these issued six contract we ’XX. Lannett. hired we also them. sell work Xth in else, Kirko. licensed six and to Lannett hired we all the by to succeed, Xth by so We Kirko, ‘XX, XXXX. We March terminated got
Prasco XXXX. We Loxapine brought terminated home by agreement the and March
a we all and [Indiscernible] Trimipramine also in instead to and had of salesperson little and go products to these with So and a Dantrolene addition makes it Amphetamine for one. Phentermine for Phendimetrazine Loxapine and that in IR ER, and Isradipine better of
to operations the our a launch products up launch commercial Elite's meaning brand, Elite label. and September mandate in set joins group the and Kirko on with
us does by third-party partners, of up explained XPL and have a Elite we here the system involved, available Xst, Because warehouse the are provider. that and distribution process to the needed he the for to XPL stands XXXX. and national months and needed ship of For set XPL pack all all operation directly with support in that. pharmacies from not of smaller that, logistics April the do to Elite's capability what pick to ANDAs Kirko to
developed to [Crossroads] So three-year for the Elite. six selected and providers up interested on with that, He he the for it specifications the to XPL providers, service We reduced process he consider contract did XPL a three bid service. RFP set to (ph). work the
distribution such He Topco, Kirko’s Optisource, Sourcing Genetics, mandate partners buying set Publix Center contracts and contracting sales, the products. LLC, ecocide XXXX. Xst, national and distributing by Premier McKesson, retailers also such on And Myers. and RX to distribution provide develop groups label Medicare Medicaid marketing CVS, Services up was CMS access AmerisourceBergen, with for as was such to for a the strategy, with Cardinal, commercial NDCs and Elite's XX of ready strategies, Walgreens, April distribution as as Elite's to
in We which and with contract business. November, in got contract the in compendium addition guys Crossroads our the had and Red to staff, delivered had the for September already had of Publix, Optisource, Oaks with all Oaks, in these Myers, in him he he XPL with the as is to signed He Premier working contracts states, XX% all XX by December. the then with in us at place October, with He well. getting listing license Golden first contracts
million is be April launch low April customer When in, estimation revenues. to dip still making June, the through our that to in going range quarter, a batches it's it's we began for to Xst going be are my Lannett coming a awards quarter. the Xst. on managed and in to March, It's $X in products be this going we commitments rough
range about made in talking we year just million. million in remember seven $X $X we're entire XXXX Now the
Elite logistics, much as this has uncontrolled reporting an in make and entire both sales, about to year. for in used now place Now controlled warehousing, financial as we and products. quarter is
it our by and to analyzing own organization. is new distribution you forward executing Goodbye. I've August talking quarter's product ANDAs it obtaining or about with explained, Elite filing to its and and first growth earnings creating We our XXth. you as reporting plan look on approvals sales
the that some sent of All so some me to And and some some questions of I'll brilliant, you right, always right give questions the to they questions, so Diane. are are honestly great as our much. feedback take the some -- of not ask of go them stockholders
sales. I'll with partnerships start first the and
would asking does doesn't sold going the then the And and issue Board on them, time at the I'm and mean announcement, first to five question or and of form. Adderall, there addressed in Elite no there Directors accepted to way product worse, where if asking, you, are of If the not five, a it or if will this single The Chinese be make decision. let's and Indian in board offer more Mikah of this. this have of the impact we for company, were an if death are same to questions, okay? oh will set SunGen when them I you're make when, boat the to about talked an be we The board or but they port, to an shape norm and and decided a and been six do in said decide are thanks I've then, SunGen yeah, in it till any offer. they it will same to is tell this going even
impact These questions done and with negative that. and to Board the on we're are create meant create gossip
to We in We're are and buy like We why a questions. didn't the sustaining are give sales in need this XXXX you to company. in serious start really starting order serious ridiculous. money Questions marketing. us
complicated the We turn I Under the having to picture this demons to but Plassche struggle definitely guys base are for on and I this around you talk tell the XR doing cannot That's to about trying, Doug the to more I'm Census really to myself mouth, barely substance. the very a we than about If what expectations controlled We and loaded, Dick sell with are IR? and not all surface. was is about. not head controlled substance, DEA for Adderall this Okay? give with and the to intelligent us. Lannett, is that's the DEA question. Very be here, trying Kirko so Code home What the to you are is work a and it will like my run hand today but will scratched a honest Elite worry question, that company, and the want the things about. and for positive hard we're you Chris don't witness permits worry
cannot But is The the good point. have needs and us market API. if sent I to that product billion API, X in to we X DEA let's numbers, make is DEA don't allow authorize, remember have they a controlling the to a To analysis see the not go get market. the they They don't units the the here. let's now. billion we DEA They say say us quota. really only developed The quota the
is and can people, it's So stuff now to tiny they these okay? are deliver need to X to drive to till it's day and million? the of show holding failure They But other a the a where being supply prices Are somebody we're up next stuff. and that shipping pharmacy wait we investigate have or little that to are really on sold, the people we're that situation? Elite in going it this straight and making evidence company one can it
will give okay. DEA. let expectations this showing this probably and but I'm we that I of answer, have least go we And to what all ER channels little a break with that happen very everybody us for going the But have well, that the do me work long times a of you would it's DEA X.X break not a goes at a XXXX course, sales, with we okay, today. through I'm so go at With double and have will the we to for that the that selling through positive contracts go My twist. have and to hoping time, Lannett. will give
But us we're us be much year, trust and sold that maybe little or under to more. I show all data, thing So them give the they'll then, up maybe about by till next selling when same more. going a Lannett pretty we
updated of XX-days any of we reasons. on abuse FDA will it in oxy We just silence supplement go word the rest or really the genetic insufflation competitive on ran study. had We Development so you, it. submitted as it radio with I questions, to because Yes, data another study? the to the
answer, will for you we'll us to to final We final going know. them let have I'm give wait answer,
Does Elite Pharmaceutical any this their extremely it's plans resume technology? Not have to deterrent costly. time, abuse at
Right The to have still that what of because that we interest Pfizer they we reasons Later blocking disbursed, before, of dollars, to the around we As better now, everything, then and foundation no interest survive. of of millions money I me way is that in SequestOx, Kirko, is the and R&D I to can parent for when mentioned. line, marketing, is taking have facility, do creating which mentioned to sales going we the for cost that. don't served a are ER forget back us go have don't. now, will have I money. when care the on, we But and the right did we a doing and we money the
nearing manufacture we wish not update to are that intend When manufacture I discuss. Pyros product. is contact but they it provide cost we This with zero is that's sold about okay? vigabatrin success. it, product ask on Please an to We year one a the them at it. launch? into plus, will genetic year thus manufacturers. the us deal a We revenues are It far. Pyros theirs, three generated We
and we product contact okay. this support will couple them them now to and We but of years in for will is manufacturers any way we for their move can on, succeed, a we'll
samples on a them. this us actually we that me week They it us our going here update ask on. sent explain they going a so let Dexcel understand are Fanish to sent Any stockholders us for in test, notification telling in to to heard Israel? from what's issue don't the
a approved We by FDA. that's product have
They this ours. plus, These mean in the would by that that We needs it doesn't approve like automatically have laws in to The either that's approved it Israelis America. let it. selling it's If than but different country. FDA, are a the product. are administrative health are they
think about me to have can. This in are able make products. not through steps order that their to they They go country is that where to, to of Dexcel think it think it's gets venture want can. is great talk a They we talking they approved? trying. exploratory they to all till specific point that opportunity, So if to may product okay. they fit get But the an They other be
our they do If that, event material Ministry is to us Please The Whatever share. compare for All for please in Israel. we can we'll ask nothing look of certain great for It Please samples they us you. compare we'll sell Israeli see is sent such end to product, go to there tell already what you approved. the to Health. nothing a as for Other really. that. they're if can when to will to discuss do. us From launch the going us is impurities do this for, have to the than it. and there's we product be we news
line senior cannot you I that on Can already have are into us. questions moved company, an on doing you changes? at please recruiters work Look work bring Plassche, acoustic months, work. front Doug small When on mountains. same the Kirko the we outstanding two, three for the that There's clarity person to in thing, did handle a provide that. unbelievable staff he all you a six some I I CFO that. got hard.
wanting sitting not in work. to hire So they and their staff a can be person corporate entire and office and
at what we be to worker all be are. that's need a Elite, You
Business was strategic a last provide company is strategies The a failed. strategies, and make this strategy to the for near-term long-term all previously long-term? as read questions Please have review. three-pronged almost to point. only communicated, that where vision I investors heading And the
because we're quarter an doing, have two, First, on company, single we we're approach, what of exist even digitize the though what small to reason the today I three-pronged done and number we every going OTC, have bulletin are one. what Number we is do. boards,
will I the questions be the not So in answering future. these are
are when maybe X%. did X.X%. at definitely, be by they It's next hitting I really if revenue we [Indiscernible] year. next the is to a fiscal by XX mandate surpass maybe full him to as is for very the one going The normal the do least next or for expect swing What her, because I going expectations and mark, March to are January. And us fiscal above to from The first current especially the And start the year, not, and this that change year quarter for we'll the crap said, million this be after, way, annoying. the CFO, quarter?
Elite question What price? events see has happened between is have the The share the on impact loss today part feel question the may first you wonderful. and material you a that of is
the part. is The second one depressing
moving. share of to As the price is I done just said, all We've lot not great proportional inversely achievement. things our happen it like good is that the share our seems and things price of a
that. the of to the more certain have been when sure throw not I am has products, move revenues, or to what want things. of meeting. have to do In I lot year I order just yet are things okay. So sales the all that in-house, can last two a get all But can I couple plan, there setting since a we in done do of of them we a up and marketing, it. Long-term, change achievements we right products from all now our moving short-term
will Elite sell can of IR with not because ER said, the Lannett we figure. our better I with Amphetamine we're other expiration financial profitability? charge products for hoping has am only the in What shape, the own the and in same destiny that Financials now impact, on if partnership As be any, revenues I
versus money I'll more whole did whole and year year. Okay, don't, sold the Why? do and they than to it, compendium He in product, he's okay? a okay, his actually orders there put whole not the in something and for certain our disclose mean. lesser did don't. products brought sell somebody it that what you Amphetamine was in Kirko they months, to and that they in IR company I they X.X they going other revenues company twice the and in it's some in selling registering Because they trying and brought the ER, XX-months in XX-weeks products, as much year. in our one of understand The
quarter, still it's yes. the first And
how pharmacist I'm assume because one step. and of amount going just pharmacy pharmacy this to your we okay? came you even five of and is it. I to do. give you're sales it's make work Well, a are a sell decide move right be wise product, to you as success, can their and department, if to other financially. them for another hoping going have one out the do other okay? because can asking mind, not we'll with, months? for the that then in if simple we cost to and you maybe I Just few product and going There us to So that I same supplemented five, But mine help the to over kind more, I'm okay? on company anymore example selling this Revenue can things we that is for next trying now, I and let's is marketing the to products you're that. now sell to the as to you what in out still focus got little that how a cost higher my have pharmacy tricky, far order next And will sell thing higher, So profit is want product, got products the mine, to it. us I only figure profitability going one a is be you a have the we of open If and to in sell a
you all from you have dilution board, the paid little why is more the As bit would cash? to I don't cash reason The me the And it. cash for you of way, because financially. by day of hey, impact taking in don't please has have Listen, nothing weird consider need because don't self-sufficient money the I pay we to salary in me one. Elite company? me your yeah, definite would been in would you the share become loaning the I'm a money. And say Would it a have than this on as is
a yes, answer or is will that. year two, So all in I'm hoping yes of the change we long-term,
at else, As we'll for talks continue of that today, that another it's only working we hopefully me everybody Board what's and and doing now, we've change it this us And year. that. out. is and cleared But right will least for the gets
you more goes as and spending sales feed to lifeline, business same are I've R&D question. R&D, Can the the R&D on release we're point our up go intelligent Hakim regarding that, go in that's be very for kind substantial setting really stockholders in question and Thank working before, and Both true a because is bloodline or where products with unless efforts? the answer you'll for the question. company Mr. effect explain press our My are That's marketing sales marketing. down yes, increase a to explained start on of we is interest on and the and is if is of important. and distribution going revenues that and that's opportunity. quite That's the out your
nice July well Elite and the be will entire August we May that It's exciting launched trajectory. distributors better I part and label. connected and we Okay. We through much that better marketing than actually. April will Xst, And man of tip-off in and the and and potential knows And was How April be to April one than launch May. Dallas going? and the spent slow study June with and as time. will there. of going traveled he's he all was well. Kirko after Launch very in week a label of to of everybody Elite's with It's and is sales going an
on have company? impact of sales of all on has I he some not new outstanding with with achievements since on job Elite. the that. has went updates department We us had an share the of leader already you done came board? through had the any Can Kirko the
six sat bring their multiple I'll minutes So to we I'll everywhere XX graduate. a you And only human call, you being, with out this, speaks minutes. in He's I IT great every that I when in, and is yes. to languages. want him that said, is XX sat a but employee. with different Kirko like I knew liked meet we them, minutes. to the people everybody not He he speed XX either I repeat XX them it They knew company families were part tell they conference also, everything with really Every a great wonderful not for XX he He car a have came fun, in man, He went really car. kicked He good their a human dating. and it's there so and another knew before hours the was said college is and family He well we educated is that them highly their is as two five, he is to company history. good knew once the being. hours each being. race, is a intelligent, spent human
long see marketing. getting in were them and that to him So of way and sales a delighted many goes
years, I months, he's else somebody take Kirko something. his six done just listening, is realized contract. think ask you to we do What is over in renegotiate Because the this Kirko is okay? going if listening? past me Diane, two to
and let he's me study going I for question okay, this, to answer. before a give and amend you right? to a have So doing two year I'm my him final say all
Well, our thank for all listening. for you meeting This concludes today.
Mathews. weekend you you, talk will Thank birthday August to America. Have a on happy wonderful and We to XX.
